PROVECTUS BIOPHARMACEUTICALS, INC.
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
PVCT$0.07+3.6%Stored close · as of Jun 30, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| March 31, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| (Unaudited) | ||
| Assets | ||
| Current Assets: | ||
| Cash | $390,435 | $307,442 |
| Restricted cash | 79,019 | 182,284 |
| Prepaid expenses and other current assets | 180,015 | 487,046 |
| Total Current Assets | 649,469 | 976,772 |
| Equipment and furnishings, less accumulated depreciation of $118,617 and $118,151, respectively | 4,396 | 4,863 |
| Operating lease right-of-use asset | 12,392 | 24,624 |
| Total Assets | $666,257 | $1,006,259 |
| Liabilities and Stockholders’ Deficit | ||
| Current Liabilities: | ||
| Accounts payable | $743,968 | $1,106,551 |
| Unearned grant revenue | 57,480 | 336,108 |
| Accrued interest | 30,533 | 27,774 |
| Accrued interest - related parties | 121,612 | 144,913 |
| Other accrued expenses | 2,204,338 | 2,175,376 |
| Notes payable | 124,578 | 206,463 |
| Convertible notes payable | 700,000 | 853,000 |
| Convertible notes payable - related parties | 1,740,000 | 2,100,000 |
| Operating lease liability, current portion | 12,729 | 25,299 |
| Total Current Liabilities | 5,735,238 | 6,975,484 |
| Total Liabilities | 5,735,238 | 6,975,484 |
| Commitments, contingencies, and litigations (Note 13) | - | - |
| Stockholders’ Deficit: | ||
| Preferred stock; par value $0.001 per share; 25,000,000 shares authorized; | ||
| Series D Convertible Preferred Stock; 957,100 shares designated at March 31, 2025 and December 31, 2024; 956,985 shares issued and outstanding at March 31, 2025 and December 31, 2024; aggregate liquidation preference of $1,643,333 and $1,095,556 at March 31, 2025 and December 31, 2024, respectively | 957 | 957 |
| Series D-1 Convertible Preferred Stock; 23,042,900 shares designated at March 31, 2025 and December 31, 2024; 13,471,623 and 13,106,223 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively; aggregate liquidation preference of $216,224,418 and $150,040,045 at March 31, 2025 and December 31, 2024, respectively | 13,471 | 13,106 |
| Common stock; par value $0.001 per share; 1,000,000,000 shares authorized; 420,279,879 shares issued and outstanding at March 31, 2025 and December 31, 2024 | 420,280 | 420,280 |
| Additional paid-in capital | 253,086,238 | 251,090,027 |
| Accumulated other comprehensive loss | (60,689) | (60,741) |
| Accumulated deficit | (258,563,069) | (257,422,961) |
| Total stockholders’ deficit attributable to Provectus Biopharmaceuticals, Inc., stockholders | (5,102,812) | (5,959,332) |
| Non-controlling interest | 33,831 | (9,893) |
| Total Stockholders’ Deficit | (5,068,981) | (5,969,225) |
| Total Liabilities and Stockholders’ Deficit | $666,257 | $1,006,259 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.